Predictors for the outcomes of patients with estrogen receptor-positive, HER2-negative advanced breast cancer treated using palbociclib plus endocrine therapy by YAMAMOTO Yutaka et al.
135Kawasaki Medical Journal 46：135－143，2020　doi：10.11482/KMJ-E202046135
Corresponding author
Junichi Kurebayashi
Department of Breast and Thyroid Surgery, Kawasaki 
Medical School, 577 Matsushima, Kurashiki, 701-0192, 
Japan
Phone : 81 86 462 1111
Fax : 81 86 462 1199
E-mail: kure@med.kawasaki-m.ac.jp
Predictors for the outcomes of patients with estrogen  
receptor-positive, HER2-negative advanced breast cancer  
treated using palbociclib plus endocrine therapy
Yutaka YAMAMOTO１）,  Ryohei OGATA１）,  Naoki KANOMATA２）,   
Emi KISHINO１）,  Takuya MORIYA３）,  Junichi KUREBAYASHI１）
1) Department of Breast and Thyroid Surgery, Kawasaki Medical School,
2) Department of Pathology, St. Luke’s International Hospital,
3) Department of Pathology, Kawasaki Medical School
ABSTRACT   A cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib (PAL), combined 
with endocrine therapy is frequently used for the treatment of patients with estrogen receptor 
(ER)-positive, human epidermal growth factor receptor (HER) 2-negative advanced breast 
cancer. However, as predictors for the outcomes remain unclear, we retrospectively investigated 
them. 
   A total of 36 patients with ER-positive, HER2-negative advanced breast cancer were treated 
using PAL plus endocrine therapy at our hospital. Treatment outcomes, objective response 
rates (ORR), progression-free survival (PFS) and post-treatment overall survival (OS) were 
analyzed. As possible predictive biomarkers, retinoblastoma protein (Rb), phosphorylated 
Rb (pRb) and different CDKs were immunohistochemically investigated using primary tumor 
tissues. Non-visceral metastasis, use of fulvestrant (FUL) and the 1st- or 2nd-line treatment were 
significant predictors for a better ORR (P = 0.0080, P = 0.0080 and P = 0.0080, respectively). 
No objective response (OR) was observed in patients with progesterone receptor (PR)-negative, 
CDK6-positive or cytosolic cyclin E1-positive tumors. Non-visceral metastasis and use of FUL 
were significant predictors for a better PFS (P = 0.0030 and P = 0.0443, respectively). The Cox 
proportional hazards model revealed that visceral metastasis (hazard ratio [HR], 4.9; P = 0.0019) 
and PR-negativity (HR, 3.2; P = 0.0411) were independent predictors for a poorer PFS. Non-
visceral metastasis, pRb-negativity and CDK6-negativity were significant predictors for a better 
OS (P = 0.0281, P = 0.0014 and P = 0.0396, respectively). The Cox proportional hazards model 
revealed that visceral metastasis (HR, 7.2; P = 0.0131) and pRb-positivity (HR, 18.5; P = 0.0060) 
were independent predictors for a poorer OS. 
   In conclusion, PR-negativity and pRb-positivity in primary tumors may be independent 
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using clinical samples demonstrated that alteration 
of the cell cycle machinery, such as mutations of the 
Rb gene, CDK6 amplification and up-regulation of 
growth factor receptor pathways, was uncommon in 
primary breast tumors and metastatic tumor cells in 
the blood and recurrent sites３－７）. Thus, there are no 
clinically applicable predictors for responsiveness 
and resistance to the combined therapy.
   To explore the clinical and biological factors 
inf luencing the outcomes of  pat ients  with 
advanced breast cancer treated by combined 
therapy, we conducted this retrospective study. 
Expression levels of possible biological factors, 
Rb, phosphorylated Rb and different CDKs, were 
immunohistochemically evaluated in primary breast 
tumors. The relationships among clinical factors, 
biological factors and clinical outcomes (objective 
response rate [ORR], PRS and OS) were analyzed.
SUBJECTS AND METHODS
Patients and treatments
   A total of 42 patients with advanced breast cancer 
were treated using PAL plus endocrine therapy 
between February 2018 and December 2019 at 
the Department of Breast and Thyroid Surgery, 
Kawasaki Medical School Hospital. Two patients 
with synchronous bilateral breast cancer and one 
patient with metachronous bilateral breast cancer 
were excluded. Four patients were diagnosed 
with HR-positive, HER2-negative tumors in 
metastatic lesions and excluded from this study. 
One patient who had a synchronous bilateral 
breast cancer was diagnosed with an HR-positive, 
HER2-negative tumor in a metastatic lesion. 
Tumor tissue samples obtained from core needle 
INTRODUCTION
   Cyclin-dependent kinase (CDK) 4/6 inhibitors, 
such as palbociclib (PAL), combined with endocrine 
therapy are markedly beneficial for patients with 
hormone receptor (HR)-positive, human epidermal 
growth factor receptor (HER) 2-negative advanced 
breast cancer. Recent clinical trials revealed that the 
addition of these CDK 4/6 inhibitors to endocrine 
therapy significantly improved progression-
free survival (PFS) and overall survival (OS) 
compared with endocrine therapy alone. These 
studies prompted physicians to commonly use the 
combination of a CDK 4/6 inhibitor and endocrine 
therapy for the treatment of patients with HR-
positive HER2-negative advanced breast cancer. 
However, de novo and acquired resistance to this 
combined therapy is frequently observed and the 
molecular mechanisms of action responsible for 
such resistance remain to be fully elucidated１）.
   A large number of preclinical and clinical 
studies have explored key molecules responsible 
for the responsiveness and resistance to CDK 4/6 
inhibitors. Alteration of cell cycle machinery, such 
as dysfunction or loss of retinoblastoma protein 
(Rb), amplification of the CDK6 gene and up-
regulation of the cyclin E1/CDK2 pathway, was 
suggested to induce resistance. Hyper-activation 
of growth factor receptor pathways, such as 
fibroblast growth factor receptor (FGFR) and HER 
3 pathways, were suggested to induce resistance. A 
down-stream signaling pathway of the growth factor 
receptor pathways, such as the PI3K/AKT/mTOR 
pathway, was also suggested to induce resistance. 
These possible biomarkers were mainly found in 
preclinical studies２）. Several translational studies 
predictors for PFS and OS, respectively. CDK6-positivity and cytosolic cyclin E1-positivity may 
be predictors for a poorer OS and ORR, respectively. Further investigation is needed to confirm 
these factors. doi：10.11482/KMJ-E202046135　(Accepted on August 28, 2020)
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biopsy (CNB) or surgically resected tumors were 
available for 36 patients. The eligibility criteria of 
this study were advanced breast cancer patients 
whose primary tumor samples were available for 
immunohistochemical (IHC) analysis.
   PAL (125 mg/body) was administered orally 
on days 1 to 21 of a 28-day cycle together with 
aromatase inhibitors every day or FUL (500 mg/
month with a loading dose). Due to adverse events 
or patient intolerance, doses of PAL were reduced 
during or from the beginning of the treatment in 18 
patients. Luteinizing hormone-releasing hormone 
was also administered to six premenopausal 
patients.
   The median age of the patients was 61 years 
(range: 42-90). All patients were female. The Eastern 
Cooperative Oncology Group performance status 
was 0 in 16 patients, 1 in 19 and 2 in 1. Fifteen had 
recurrent diseases and 11 had stage IV diseases. 
Target lesions were soft tissues in 21 patients, 
bones in 23, the lungs in 17 and the liver in 14. The 
median number of previous endocrine therapies 
was 3 (range: 1-10). Long-stable disease (L-SD, SD 
for over 6 months) was achieved by the previous 
endocrine therapy in 18. The line of treatment for 
PAL therapy was the 1st or 2nd in 15 patients and the 
3rd or later in 21. Chemotherapeutic agents were 
administered as adjuvant or recurrence therapy 
before PAL therapy in 18. Due to serious adverse 
effects, such as neutropenia and liver dysfunction, 
PAL therapy was discontinued in three patients. The 
median follow-up time was 16.5 months (range: 
2-26). The background characteristics of the patients 
are summarized in Table 1.
IHC analysis
   As CNB samples were fixed more appropriately 
for immunostaining, IHC results using the CNB 
samples were adopted for analysis in this study.
   Expression levels of the estrogen receptor (ER) 
and progesterone receptor (PR) were evaluated 
using the anti-ER monoclonal antibody 1D5 (1:50 
dilution; Dako, Glostrup, Denmark) and anti-PR 
monoclonal antibody PgR636 (1:800 dilution; 
Dako), respectively. The cut-off value for both ER 
and PR positivity was 1%. HER2 expression was 
assessed by IHC using HercepTest (Dako). The 
results were evaluated according to the criteria of 
Table 1. Background characteristics of the study subjects




Diseases Stage IV 11
Recurrence 15




Number of previous endocrine therapies 1 - 10 (median, 3)
Effects of previous endocrine therapy L-SD 18
SD or PD 18
First- or 2nd-line use Yes 15
No 21
Previous chemotherapy Yes 18
No 18
Discontinuation by adverse events Yes 3
No 33
Follow-up time (months) 2 - 26 (median, 16.5)
PS, performance status; L-SD, long stable disease (for over 6 months); PD, progressive disease
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the HercepTest. Paraffin-embedded tissue sections 
(4-μm thick) were analyzed using the FISH 
protocol (Vysis, Downers Grove, IL, USA). An 
HER2/CEP17 ratio equal to or greater than 2.0 was 
interpreted as positive for gene amplification.
   R e g a r d i n g  e x p l o r a t o r y  b i o m a r k e r s , 
immunostaining was performed using an EnVision 
Plus kit (Agilent, Santa Clara, CA, USA). Four-μ
m sections were cut from formalin-fixed paraffin-
embedded blocks. After dewaxing and hydration, 
they were placed in a bath of Target Retrieval 
Solution, pH 9.0 (Agilent) at 95℃for 40 min for 
CDK4 (DCS-31, Thermo Fisher Scientific, Waltham, 
MA), CDK6 (EPR4515, Abcam, Cambridge, UK), 
Rb (4H1, Cell Signaling Technology, Danvers, MA) 
and phospho-Rb (pRb) (Ser807/811) (D20B12, 
Cell Signaling), or of citrate buffer, pH 6.0 for 
cyclin D1 (SP4, Thermo Fisher Scientific) at 95℃
for 40 min. The sections were incubated with the 
primary antibodies overnight at 4℃. The dilutions 
Table 2. Primary antibodies and staining conditions
Antigen Clone (manufacturer) Dilution Retrieval
Rb 4H1, mouse mono (Cell Signaling Technology) x 800 TRS
pRb Ser807/811 D20B12, rabbit mono (Cell Signaling Technology) x 500 TRS
CDK4 DCS-31, mouse mono (Thermo Fisher Scientific) x 50 TRS
CDK6 EPR4515, rabbit mono (Abcam) x 100 TRS
cyclin D1 SP4, rabbit mono (Thermo Fisher Scientific) x 50 citrate buffer
cyclin E1 E-4, mouse mono (Santa Cruz Biotechnology, Inc.) x 100 no
Rb, retinoblastoma protein; TRS, tris-buffered saline; pRb, phosphorylated Rb; CDK, cyclin-dependent kinase
of primary antibodies were: 1:50 for CDK4 and 
cyclin D1, 1:100 for CDK6 and cyclin E1 (E-4, 
Santa Cruz Biotechnology, Inc, Dallas, TX), 1:500 
for pRb and 1:800 for Rb. The chromogen used 
was 3,3’ -diaminobenzidine tetrachloride and the 
sections were counterstained with hematoxylin. 
The immunohistochemical expression area (%) at 
any intensity was evaluated. A summarized IHC 
protocol is shown in Table 2.
Evaluation of IHC data
   The cut-off values of the respective biomarkers 
were defined as the median values of their 
percentages of positively stained cells. However, as 
a small percentage of cells was positively stained 
for CDK6, and nuclear or cytosolic cyclin E1, their 
cut-off values were defined as 1% of the percentage 
of positively stained cells. A representative 
immunostaining image for each biological factor is 
shown in Fig. 1.
Figure 1
a b c d
e f g h
Fig. 1. Representative IHC staining for CDK4 (a), CDK6 (b), Rb (c), pRb (d), cyclin D1 (e), nuclear cyclin E1 (f) and 
cytoplasmic cyclin E1 (g). Negative control (h).
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Clinical outcome and statistical analysis
   Clinical responses to PAL therapy were evaluated 
according to the Response Evaluation Criteria in 
Solid Tumors (RECIST) criteria. Changes in serum 
tumor markers, such as CA 15-3, were used to 
assist in evaluating clinical responses. Relationships 
between predictive factors and objective response 
(OR, complete response [CR] plus partial response 
[PR]) were assessed by the Fisher’s exact test. 
   PFS was defined as the time from the beginning 
of PAL therapy to disease progression or death from 
any cause. The patients who had severe adverse 
events and discontinued PAL therapy were censored 
at the time of discontinuation. The PFS rate was 
estimated according to the Kaplan-Meier method 
and univariate comparisons between groups were 
made using the log-rank test. 
   OS was defined as the time from the beginning 
of PAL therapy to death from any cause. The OS 
rate was estimated according to the Kaplan-Meier 
method and univariate comparisons between groups 
were made using the log-rank test. 
   The effects of predictive factors on PFS and OS 
were quantified in terms of hazard ratios (HRs), 
estimated and adjusted using the Cox proportional 
hazards model. All tests were two-tailed and P < 0.05 
was considered to be significant. Statistical analyses 
were performed using StatView software (SAS 
Institute Inc., Tokyo, Japan).
   Possible clinical and biological factors influencing 
the outcomes of patients treated using PAL therapy 
are listed in Table 3. Only clinically predictive 




   To explore predictive factors for anti-tumor 
activity of PAL therapy, clinical and biological 
factors influencing OR were investigated. Based on 
the Fisher’s exact test, non-visceral metastasis, use 
of fulvestrant (FUL) and the 1st- or 2nd-line treatment 
were significant predictors for a better ORR (P = 
0.0080, P = 0.0080 and P = 0.0080, respectively). 
Of note, no OR was observed in patients with PR-
negative, CDK6-positive or cytosolic cyclin E1-
positive tumors (Table 4).
Predictors for PFS
   To explore predictive factors for tumor-controlling 
activity of PAL therapy, clinical and biological 
factors influencing PFS were investigated. Based 
on the log-rank test, non-visceral metastasis and use 
of FUL were significant predictors for a better PFS 
(P = 0.0030 and P = 0.0443, respectively). The 50% 
PFS and P-values are shown in Table 5. The Kaplan-
Table 3. Possible predictors for outcomes of patients treated using PAL therapy
Clinical factors Biological factors
Cut-off values Cut-off values
Age 50 years or younger/older ER 1%
PS 0/1 or more PR 1%
Visceral metastasis Yes/No HER2 0/ 1+ or 2+
Liver metastasis Yes/No Rb 50%
Bone-only metastasis Yes/No pRb 4%
Previous chemotherapy Yes/No CDK4 65%
Number of previous endocrine therapies 1 or 2/3 or more CDK6 1%
Treatment line 1st or 2nd/3rd or later cyclin D1 50%
L-SD achieved by previous endocrine therapy Yes/No nuclear cyclin E1 1%
Combined endocrine therapy FUL/not cytosolic cyclin E1 1%
Dose reduction of PAL Yes/No
PAL, palbociclib; PS, performance status; L-SD, long stable disease; ER, estrogen receptor; PR, progesterone receptor; 
HER, human epidermal growth factor receptor; Rb, retinoblastoma protein; pRb, phosphorlated Rb; CDK, cyclin-dependent kinase
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Meier curves for the two factors are shown in Fig. 2.
   According to the Cox proportional hazards model, 
visceral metastasis (hazard ratio [HR], 4.9; 95% 
confidence interval [95% CI], 1.8 - 13.3; and P = 
0.0019) and PR-negativity (HR, 3.2; 95% CI, 1.0 - 
9.5; and P = 0.0411) were independent predictors 
for a poorer PFS.
Predictors for OS
   Clinical and biological factors influencing OS 
after starting PAL therapy were investigated. Based 
on the log-rank test, non-visceral metastasis, pRb-
negativity and CDK6-negativity were significant 
predictors for a better OS (P = 0.0281, P = 0.0014 
and P = 0.0396). The 50% PFS and P-values are 
shown in Table 6. The Kaplan-Meier curves for the 
three factors are shown in Fig. 3.
   According to the Cox proportional hazards model, 
visceral metastasis (HR, 7.2; 95% CI, 1.5 - 33.4; 
and P = 0.0131) and pRb-positivity (HR, 18.5; 95% 
CI, 2.3 - 142.9; and P = 0.0060) were independent 
predictors for a poorer OS.
DISCUSSION
   We performed this retrospective study to explore 
possible predictors for the outcomes of patients with 
HR-positive, HER2-negative advanced breast cancer 
treated using the combination of PAL and endocrine 
therapy. We selected several biological factors 
related to ER signaling and cell cycle-associated 
molecules based on the results of recent preclinical 
and translational studies２）. The expression levels 
of these biological factors in primary breast 
tumors were evaluated by the IHC method. We 
also analyzed several clinical factors hypothesized 
to influence the outcomes of the treated patients. 
Table 4. Predictors for ORR
Possible predictors ORR P-value
Non-visceral metastasis Yes 33.3% (5/15) 0.0080
No 0% (0/21)
FUL use Yes 33.3% (5/15) 0.0080
No 0% (0/21)
First- or 2nd-line treatment Yes 33.3 % (5/15) 0.0080
No 0% (0/21)
PR Positive 17.9% (5/28) 0.5585
Negative 0% (0/7)
CDK6 Positive 0% (0/5) > 0.9999
Negative 16.1% (5/31)
cytosolic cyclin E1 Positive 0% (0/9) 0.3017
Negative 18.5% (5/27)
































Fig. 2. The Kaplan-Meier curves of PFS in patients treated 
using PAL therapy stratified by presence (closed circles) or 
absence (open circles) of visceral metastasis (a) and use (open 
circles) or non-use (closed circles) of FUL (b).
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This study revealed several factors related to the 
responsiveness and the resistance to PAL-containing 
therapy.
   Regarding the clinically predictive factors, non-
visceral metastasis, FUL as a combination partner 
and 1st- or 2nd-line use for the treatment of advanced 
breast cancer were significant predictors for better 
outcomes of patients treated using PAL therapy. It 
is well known that visceral metastasis is unlikely to 
respond to endocrine therapy compared with non-
visceral metastasis. Therefore, the combination of 
endocrine therapy and PAL may be more efficacious 
for non-visceral metastasis than visceral metastasis. 
Indeed, non-visceral metastasis was a significant 
predictor for the ORR, PFS and OS in this study 
(Tables 4-6, Figs. 2, 3). The combined use of FUL 
and PAL was suggested to be more potent than that 
of an aromatase inhibitor and PAL (Table 4). As 
the median number of previous endocrine therapies 
before PAL therapy was three, most patients in 
this study previously received different types of 
endocrine therapy (Table 1). Thus, the combined 
use of FUL being more efficacious than that of an 
aromatase inhibitor may be reasonable. In addition, 
it is well known that 1st-line use of antitumor 
agents is more effective than their later use. It may 
therefore be reasonable that the 1st- or 2nd-line use 
of PAL therapy was more efficacious than the 3rd- or 
later line use (Table 4).
   The multivariate analysis revealed that PR-
negativity in primary breast tumors was an 
independent predictor for a poorer PFS in this study. 
A translational study using samples obtained from 
a large prospective randomized study, POLOMA-3, 
demonstrated that a lower expression level of PR 
correlated with a poor response to combined PAL 
Table 5. Predictors for PFS
Possible predictors 50% PFS P-value
Non-visceral metastasis Yes 18.2 0.0030
No 3.2
FUL use Yes 12.1 0.0443
No 5.0
PR Positive 6.4 0.4977
Negative 4.0
CDK6 Positive 2.6 0.1404
Negative 6.1
PFS, progression-free survival;  FUL, fulvestrant;  PR, 
progesterone receptor; CDK, cyclin-dependent kinase
Table 6. Predictors for OS
Possible predictors 50% OS P-value
Non-visceral metastasis Yes 25.0 0.0281
No 21.3
pRb Positive 15.6 0.0014
Negative NR
CDK6 Positive 12.6 0.0396
Negative 24.8
OS, overall survival; pRb, phosphorylated retinoblstoma protein; 















































Fig. 3. The Kaplan-Meier curves of OS in patients treated 
using PAL therapy stratified by the presence (closed circles) 
or absence (open circles) of visceral metastasis (a), pRb-
positive (closed circles) or -negative (open circles) (b) and 
CDK6-positive (closed circles) or -negative (open circles) 
(c). 
142 Kawasaki Medical Journal
and FUL therapy４）. PR-negativity in ER-positive 
breast tumors is an important predictor for a poorer 
response to endocrine therapy. PR expression may 
be also a predictor for response to combined PAL 
and endocrine therapy.
   Regarding the exploration of biological factors for 
predicting patient outcomes, Rb loss or dysfunction 
was reported to cause de novo or acquired resistance 
to CDK4/6 inhibitors２）. However, Rb negativity 
was not a significant predictor for the ORR, PFS 
or OS in this study. In contrast, pRb positivity 
was an independent predictor for OS (Table 6). 
It is well known that pRb is an activated form of 
Rb mediated by the cyclin D/CDK4/6/Rb/E2F 
pathway that regulates the G1-S transition in the 
cell cycle. Lower expression levels of Rb were 
reported to correlate with a shorter PFS of patients 
with metastatic breast tumors treated using PAL-
containing therapy in one translational study８）, but 
not in another study７）. There is no published report 
on the relationship between basal pRb expression 
levels in breast tumors and outcomes of patients 
treated using a CDK4/6 inhibitor and endocrine 
therapy. Rb activation by other growth-promoting 
pathways, such as growth factor receptor pathways, 
in breast tumors may induce malignant progression 
and deteriorate the patient outcome. 
   The expression levels of CDK4 and CDK6 
were hypothesized to correlate with responses to 
CDK4/6 inhibitor-containing therapy. Although 
CDK4 expression in primary breast tumors was 
not correlated with the outcomes of patients treated 
using PAL therapy, CDK6 expression was correlated 
with the ORR, PFS and OS in this study (Tables 4 - 
6, Fig. 3). In preclinical models, gene amplification 
or overexpression of CDK6 was noted after the 
acquisition of resistance to CDK4/6 inhibitors in 
ER-positive, HER2-negative breast cancer cell 
lines９，10）. This suggests that CDK6 overexpression 
plays an important role in the development of 
resistance to CDK4/6 inhibitors. In contrast, as 
previously reported by a translational study11）, 
cyclin D1 expression was not correlated with the 
outcomes of the patients in this study.
   Although CDK4/6 plays an essential role in the 
phosphorylation of Rb and cell cycle transition from 
the G1 to S phase, the cyclin E1/CDK2 pathway 
is also known to phosphorylate Rb and promote 
G1-S transition２）. Abnormal activation of the 
cyclin E1/CDK2 pathway was previously suggested 
to promote resistance to CDK4/6 inhibitors in 
preclinical studies２，８）. In particular, overexpression 
of cytosolic cyclin E1 was reported to be a candidate 
factor for the resistance to CDK4/6 inhibitors８）. No 
OR was achieved by PAL therapy in patients with 
primary breast tumors expressing cytosolic cyclin 
E1 (Table 4), but cytosolic cyclin E1 expression was 
not correlated with the PFS or OS in this study. 
   There are some limitations in this study. The 
number of study subjects was small, the outcomes of 
the patients were not precisely evaluated because of 
the retrospective observation, the expression levels 
of biological factors were examined in primary 
breast tumors, but not in metastatic or recurrent 
lesions, and the evaluation of their expression levels 
was not standardized. However, this study suggested 
that biological factors, such as PR, pRb, CDK6 and 
cytosolic cyclin E1, in primary tumors can predict 
the outcomes of patients with ER-positive, HER2-
negative advanced breast cancer treated using PAL 
and endocrine therapy. These biological factors 
may be useful to select advanced breast cancer 
patients who should be treated or not with PAL and 
endocrine therapy.
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